Angiotensin Receptor-Neprilysin Inhibitors Emerge as Potential Treatment for Acute Myocardial Infarction

J Am Coll Cardiol. 2018 Nov 6;72(19):2357-2359. doi: 10.1016/j.jacc.2018.08.2170.

Authors

David J Lefer¹, Thomas E Sharp 3rd²

Affiliations

¹ Cardiovascular Center of Excellence, School of Medicine, LSU Health Science Center, New Orleans, Louisiana; Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana. Electronic address: [email protected].
² Cardiovascular Center of Excellence, School of Medicine, LSU Health Science Center, New Orleans, Louisiana.

PMID: 30384892
DOI: 10.1016/j.jacc.2018.08.2170

No abstract available

Keywords: LCZ696; acute myocardial infarction; preclinical translational research.

Publication types

Editorial
Comment

MeSH terms

Aminobutyrates
Animals
Biphenyl Compounds
Drug Combinations
Infarction
Myocardial Infarction*
Neprilysin*
Rabbits
Receptors, Angiotensin
Tetrazoles
Valsartan
Ventricular Remodeling

Substances

Aminobutyrates
Biphenyl Compounds
Drug Combinations
Receptors, Angiotensin
Tetrazoles
Valsartan
Neprilysin
sacubitril and valsartan sodium hydrate drug combination